Current Bioinformatics13, Issue 2

Current Pediatric Reviews 13, Issue 4

Current Organic Chemistry 22, Issue 3

Current Drug Metabolism 19, Issue 1

Current Medicinal Chemistry 25, Issue 9

Current Pharmaceutical Biotechnology 18, Issue 13



Recent Patents on Engineering 12-1

Current Molecular Medicine 17-7

Letters in Organic Chemistry 15-4

Letters in Drug Design & Discovery 15-4

Current Pharmaceutical Biotechnology 18-12


EDITOR’S CHOICE – Biologics in Inflammatory and Immunomediated Arthritis – Current Pharmaceutical Biotechnology

Journal:  Current Pharmaceutical Biotechnology

Author(s): Michele M. Luchetti*, Devis Benfaremo, Armando Gabrielli.


Background: Biologic drugs, introduced in clinical practice almost twenty years ago, represent nowadays a prominent treatment option in patients with chronic inflammatory arthritis, such as Rheumatoid Arthritis, Psoriatic Arthritis and Spondyloarthritis, that include ankylosing spondylitis and non-radiographic axial spondyloarthritis.

Methods: Several compounds targeting different pathways have been marketed and approved for the treatment of inflammatory arthritis, with a significant impact on the clinical outcomes and the natural history of the diseases.

Results: There are currently seven classes of biologics that are available for the treatment of inflammatory arthritis, each inhibiting a different aspect of the immune-driven inflammatory pathway.

They include:

• Tumor Necrosis Factor (TNF) inhibitors (infliximab, adalimumab, etanercept, golimumab and certolizumab pegol);

• Interleukin-1 (IL-1) receptor antagonists (anakinra);

• Interleukin-6 (IL-6) inhibition (tocilizumab);

• Interleukin-12/23 (IL23) inhibition (ustekinumab);

• Interleukin-17 (IL-17) inhibition (secukinumab);

• B-cell inhibition (anti-CD20, rituximab);

• T-cell costimulation inhibition (anti-CTLA-4, abatacept).

Conclusion: In this review, we will focus on the role of biologic drugs in the treatment strategies for inflammatory arthritis.

Read more here:




Current Protein & Peptide Science Volume 19, Issue 4

Combinatorial Chemistry & High Throughput Screening Volume 20, Issue 10

Current Pharmaceutical Biotechnology Volume 18, Issue 11

Endocrine, Metabolic & Immune Disorders – Drug Targets Volume 18, Issue 2

Mini-Reviews in Medicinal Chemistry Volume 18, Issue 5

Current Drug Delivery Volume 15, Issue 2


MOST ACCESSED ARTICLE – The Use of Biomarkers in Sepsis – Current Pharmaceutical Biotechnology

Journal: Current Pharmaceutical Biotechnology

Author(s): Konstantinos Giannakopoulos*, Ursula Hoffmann, Uzair Ansari, Thomas Bertsch, Martin Borggrefe,Ibrahim Akin, Michael Behnes

Graphical Abstract:



Background: Despite the extended laboratory and clinical study of sepsis, its diagnosis remains a clinical challenge. The initiation of sepsis activates many different biochemical and immunological pathways being expressed by alterations of various molecules in human tissues. The detection and measurement of the concentration of such molecules, known as biomarkers, may be a diagnostic tool of great significance for clinicians dealing with suspected sepsis. Additionally, biomarkers may predict patients ´ outcome and may play a role in monitoring response to therapy.

Methods: Most relevant clinical and experimental biomarker studies on sepsis were retrieved and reviewed in this article.

Results: Although many biomarkers were evaluated for the diagnosis and prognosis in sepsis, until now not one has been proven to be absolutely reliable in the clinical field. Currently C-reactive proteine (CPR) and procalcitonin (PCT) are used worldwide routinely, nevertheless their values may elevate in clinical settings without sepsis, while they often fail to provide reliable prediction of the patient outcome.
Conclusion: This review outlines most relevant circulating biomarkers in sepsis.
To access the article, please visit:


PRESS RELEASE FOR EUREKALERT! Anti-tumor and immune-potentiating Enterococcus faecalis-2001 β-glucans

This article by Dr. Yeun-Hwa Gu et al. has been published in Current Pharmaceutical Biotechnology, Volume 18, Issue 8, 2017


Background: Enterococcus faecalis 2001 is a probiotic lactic acid bacterium and has been used as a biological response modifier (BRM). From physiological limitation of bacterial preservation in storage and safety, the live E. faecalis 2001 has been heat-treated and the BRM components containing high level of β-glucan, named EF-2001, were prepared.

Method: The heat-treated EF-2001 has been examined for the antioxidative potential for radical scavenging and anti-tumor activities as well as immune-enhancing response in mice. Lymphocyte versus polymorphonuclear leukocyte ratio was increased in mice upon treatment with EF-2001. The number of lymphocytes was increased in the EF-2001-treated group. In the mice bearing two different Ehrlich solid and Sarcoma-180 carcinomas, the treatment with EF-2001 resulted in anti-tumor action. Tumor-suppressive capacity upon treatment with EF-2001 was significantly increased compared to normal controls.

Results: During the time interval administration of 5 weeks between the priming and secondary administration of EF-2001, the expression and production levels of TNF-α were also observed in the EF-2001administered mice. Additionally, anti-tumor activity examined with the intravenous administration of EF 2001 with a 34 time intervals was also observed, as the growth of Sarcoma180 cells was clearly inhibited by the EF-2001.

Conclusion: From the results, it was suggested that the immune response is enhanced due to antioxidative activity caused by the EF-2001 and anti-tumor activity by NK cells and TNF-α.

For more information about the article, please visit


Current Pharmaceutical Biotechnology 18-8

Current Biotechnology 6-4

Current Neuropharmacology 15-8

Current Cancer Therapy Reviews 13-2

Current Pharmaceutical Design 23-29

Mini-Reviews in Organic Chemistry 14-6

Current Organic Chemistry 21-22

Current Medical Imaging Reviews 13-4

Current Proteomics 14-4

Endocrine, Metabolic & Immune Disorders – Drug Targets 17-4


SMi EVENT – 7th annual Pharmaceutical Microbiology!

SMi Group is thrilled to present the 7th annual Pharmaceutical Microbiology taking place on 22nd – 23rd January 2018 in London, UK.

200 x 200 copy

SMi’s 7th annual Pharmaceutical Microbiology UK conference will provide attendees essential indicators for Quality Assurance and Quality Control whilst presenting that latest information on protecting pharmaceutical and healthcare products from spoilage by microorganisms, and protecting patients and consumers.

This 2018 event will provide an in-depth overview of the function of the pharmaceutical microbiologist and what they need to know, from regulatory filing and GMP, to laboratory design and management, and risk assessment tools and techniques. These key aspects are discussed through a series of dedicated presentations, keynote sessions and workshops, with topics covering biofilms, validation, data analysis, bioburden, toxins, microbial identification, mycoplasma testing, and contamination control.


  • Oliver Chancel, Sterility and Aseptic Process, Assurance Expert, Merial Sas
  • Andrew Bartko, Research Leader, Battelle Memorial Institute

Expert Speaker Line-Up Features:

  • Renate Rosengarten, Professor and Chair of Bacteriology and Hygiene, University of Veterinary Medicine Vienna
  • Ingo Spreitzer, Deputy Head Section Microbial Safety, Paul-Ehrlich Institute
  • Ruth Daniels, Senior Scientist Microbiology, Janssen
  • Jeremy Webb, Professor of Microbiology, Principal Investigator (Biofilms and Microbial Communities), University of Southampton
  • Shahram Lavasani, CEO & Founder, ImmuneBiotech

Exclusive highlights in 2018:

  • Hear about new mycoplasma testing methods to optimise contamination control
  • Gain insight from a regulatory perspective on ways to make testing methods compliant
  • Explore actual implementation of rapid microbial methods within a laboratory setting, that meet regulatory requirements
  • Gain an in-depth understanding of biofilms and why they pose such an issue in terms of drug development and delivery
  • Receive updates on the current research being done to circumvent the issues posed by biofilms

For more information visit the website at or contact the team on email: or call +44 (0) 207 827 6012

Journal: Current Pharmaceutical Biotechnology

EBook: Frontiers in Anti-Infective Drug Discovery 


New Issue :: Current Pharmaceutical Biotechnology 18, Issue 3

Current Pharmaceutical Biotechnology aims to cover all the latest and outstanding developments in Pharmaceutical Biotechnology. Each issue of the journal contains a series of timely in-depth reviews, research articles and letters written by leaders in the field covering a range of current topics in both pre-clinical and clinical areas of Pharmaceutical Biotechnology. Current Pharmaceutical Biotechnology is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments.

Current Pharmaceutical Biotechnology is excelling in impact to be the number one journal in its field.


Articles from the journal Current Pharmaceutical Biotechnology 18, Issue 3:

                       For details on the articles, please visit this link ::


Highlighted Article Flyer for the journal “Current Pharmaceutical Biotechnology”

CPB-Articles_18-15- Giorgio Walter Canonica]